KBC Group
JANX icon

KBC Group’s Janux Therapeutics JANX Stock Holding History

KBC Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,387
Closed -$19K – 1861
2026
Q1 		$19K Hold
1,387
– – ﹤0.01% 1842
2025
Q4 		$19K Hold
1,387
– – ﹤0.01% 1726
2025
Q3 		$34K Hold
1,387
– – ﹤0.01% 1714
2025
Q2 		$32K Sell
1,387
-1,074
-44% -$28.3K ﹤0.01% 1695
2025
Q1 		$66K Buy
+2,461
New +$92.8K ﹤0.01% 1704

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

KBC Group's JANX Position: Q2 2026 in Review

KBC Group sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 1,387 shares — an estimated $19K sold.

KBC Group first reported a position in JANX in Q1 2025 and held it in 5 quarters. The position peaked at $66K in Q1 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • KBC Group reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
  • KBC Group sold 1,387 Janux Therapeutics shares in Q2 2026, an estimated $19K.
  • KBC Group first reported a position in Janux Therapeutics in Q1 2025 and held it in 5 quarters.
  • KBC Group's Janux Therapeutics position peaked at $66K in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.